• Annual Meeting
  • News
  • Donate
  • Contact
  • HSG Clinical Trials & Research
    • About Clinical Trials
    • Current HSG Trials
      • PROOF-HD
        • PROOF-HD: Study Locations
        • PROOF-HD: FAQs
      • KINECT-HD2
      • KINECT-HD
        • KINECT-HD: Study Locations
        • KINECT-HD: FAQs
        • KINECT-HD: About HD
        • KINECT-HD: About Clinical Studies
    • Past HSG Research Trials & Studies
    • HSG Credentialed Sites
    • Contact Me About Future Research
  • myHDstory™
  • HSG Credentialing & Membership
    • Get Credentialed for HD Research
    • Become a HSG Member
      • HSG Membership Application
      • HSG Associate Member Application
  • Education & Care
    • CME4HD – Accredited Learning
    • HD Care Education Videos
    • HD Care and Treatment Resources
    • HD Care Improvement Project
    • Disclaimer of Medical Advice
  • Other HSG Resources
    • UHDRS® – Unified Huntington’s Disease Rating Scale
      • UHDRS® Request Form
    • HD Insights
      • Periodical (e-version)
      • HD Insights Podcast
    • Publications
  • Living with HD
    • HD Basics
    • HD Quiz: Myths & Facts
    • HD Drug Pipeline
    • I AM THE DIFFERENCE!
  • About HSG
    • What is the HSG?
    • Our Services
      • Research Advisory Board
    • Our Accomplishments
    • Our Organization
      • HSG Board
      • Executive Committee
      • HSG Staff
    • Our Annual Meeting
      • HSG 2022
      • Past Annual Meetings
    • Careers

Neurocrine Biosciences Announces Positive Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease

Share This

SAN DIEGO, Dec. 7, 2021 – Neurocrine Biosciences (Nasdaq: NBIX) today announced positive top-line data from its Phase 3 KINECT-HD study evaluating the efficacy, safety and tolerability of valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor being investigated as a once-daily treatment in adults with chorea associated with Huntington disease (HD).

View full press release.

Previous Post
Huntington Study Group Announces A Partnership with Prilenia Therapeutics to Conduct A Global Phase 3 Clinical Study of Pridopidine in Huntington’s Disease
News, Press Releases
Next Post
Huntington Study Group Enrolls First Participant for Its Observational Study to Test the Reliability of the Virtual Use of the  Unified Huntington’s Disease Rating Scale® in Clinical Trials for Huntington’s Disease
News, Press Releases

Related Posts

Huntington Study Group Names First Chief Innovation Officer
Huntington Study Group Names First Chief Innovation Officer
Huntington Study Group Annual Meeting
Huntington Study Group Annual Meeting
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
Huntington Study Group Announces Results from the HD-Net Assessment on the State of Care for Huntington’s Disease in the United States
Huntington Study Group Announces myHDstory™ Pilot Study:  Making HD Voices ­­­Heard Has Reached Target Enrollment
  • Quick Links

    Find a HSG Trial or Study
    Get Credentialed for HD Research
    Accredited Training on HD (CME4HD)
    HSG Annual Meeting
    UHDRS®
    Disclaimer of Medical Advice
    HSG Code of Conduct

  • Applications + Forms

    HSG Member Application
    Associate Member Application
    Member Update Submission
    Investigator Application
    Coordinator Application
    New Site Application
    Site Letter of Agreement 
    UHDRS® Request Form
    Future Research Contact Form

  • Contact HSG

    Huntington Study Group 95 Allen’s Creek Road
    Building 1, Suite 132
    Rochester, NY 14618, USA

    Toll Free (North America): 800-487-7671
    Fax: 585-672-9912

    Email: info@hsglimited.org  

                    

Copyright © 2021 Huntington Study Group. All Rights Reserved. | Privacy Statement | Terms of Use | Financial Disclosures